Successful market access for gene therapies version 2.0

In 2018, SKC wrote a comprehensive white paper that examined the strategic challenges and possible solutions for a successful market access of gene therapies. This paper has now been updated by Dr. Esther Kenfack and Prof. Dr. Matthias P. Schönermark and is available in version 2.0. Please feel free to request a free copy below. 

In this white paper, a comprehensive analysis of the current regulatory aspects of gene therapies in the US and Europe addresses both existing requirements as well as potential opportunities and risks in market entry. The thorough analysis of precedents provides an overview of the underlying evidence and the current reimbursement scenery for gene therapies already on the market. Since the novelty of gene therapies involves many uncertainties in market entry especially in the reimbursement of on-time administration, the white paper presents possible reimbursement models and makes recommendations for a successful market access.

SKC is a leading strategy consultancy in the German healthcare sector. Our expertise in the field of gene therapies is supported by over 15 years of experience in market approval. We are deeply devoted to offer innovative and valuable solutions to our clients.